Professor Kenneth Williams

Graham GG; Milligan MK; Day RO; Williams KM; Ziegler JB, 1998, 'Therapeutic considerations from pharmacokinetics and metabolism: Ibuprofen and paracetamol', in Rainsford KD; Powanda MC (ed.), SAFETY AND EFFICACY OF NON-PRESCRIPTION (OTC) ANALGESICS AND NSAIDS, SPRINGER, SAN FRANCISCO, CA, pp. 77 - 92, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000081416000006&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conaghan PG; Lehmann T; Brooks P, 1997, 'Disease-modifying antirheumatic drugs', in Current Opinion in Rheumatology, edn. 3, pp. 183 - 190, http://dx.doi.org/10.1097/00002281-199705000-00003

Graham GG; Milligan MK; Day RO; Williams KM; Zeig, 1997, 'Therapeutic considerations from pharmacokinetics and metabolism: ibuprofen and paracetamol', in In: `Safety and efficacy of non-prescription (OTC) analgesics, edn. Original, Kluwer Academic Publishers, Great Britain, pp. 77 - 92

Vesey G; Ashbolt NJ; Wallner G; Dorsch R; Williams KM; Veal DA, 1995, 'Assessing cryptosporidium parvum oocyst viability with fluorescent in situ hybridization using ribosomal RNA probes and flow cytometry', in Protozoan parasites and water, edn. Original, Royal Society of Chemistry, Cambridge, pp. 133 - 138

Kannangara DRW; Graham GG; Wright DFB; Stocker SL; Portek I; Pile KD; Barclay ML; Williams KM; Stamp LK; Day RO, 2017, 'Individualising the dose of allopurinol in patients with gout', British Journal of Clinical Pharmacology, vol. 83, pp. 2015 - 2026, http://dx.doi.org/10.1111/bcp.13307

Duong JK; Kroonen MYAM; Kumar SS; Heerspink HL; Kirkpatrick CM; Graham GG; Williams KM; Day RO, 2017, 'A dosing algorithm for metformin based on the relationships between exposure and renal clearance of metformin in patients with varying degrees of kidney function', European Journal of Clinical Pharmacology, vol. 73, pp. 981 - 990, http://dx.doi.org/10.1007/s00228-017-2251-1

Day RO; Kannangara DRW; Stocker SL; Carland JE; Williams KM; Graham GG, 2017, 'Allopurinol: insights from studies of dose–response relationships', Expert Opinion on Drug Metabolism and Toxicology, vol. 13, pp. 449 - 462, http://dx.doi.org/10.1080/17425255.2017.1269745

Kamel B; Graham GG; Williams KM; Pile KD; Day RO, 2017, 'Clinical Pharmacokinetics and Pharmacodynamics of Febuxostat', Clinical Pharmacokinetics, vol. 56, pp. 459 - 475, http://dx.doi.org/10.1007/s40262-016-0466-4

Day RO; Kamel B; Kannangara DRW; Williams KM; Graham GG, 2016, 'Xanthine oxidoreductase and its inhibitors: Relevance for gout', Clinical Science, vol. 130, pp. 2167 - 2180, http://dx.doi.org/10.1042/CS20160010

Vaccher S; Kannangara DRW; Baysari MT; Reath J; Zwar N; Williams KM; Day RO, 2016, 'Barriers to care in gout: From prescriber to patient', Journal of Rheumatology, vol. 43, pp. 144 - 149, http://dx.doi.org/10.3899/jrheum.150607

Martinello M; Schteinman A; Alavi M; Williams K; Dore GJ; Day R; Matthews GV, 2016, 'The impact of ribavirin plasma concentration on the efficacy of the interferon-sparing regimen, sofosbuvir and ribavirin', ANTIVIRAL THERAPY, vol. 21, pp. 127 - 132, http://dx.doi.org/10.3851/IMP2984

Smith FC; Kumar SS; Furlong TJ; Gangaram SV; Greenfield JR; Stocker SL; Graham GG; Williams KM; Day RO, 2016, 'Pharmacokinetics of Metformin in Patients Receiving Regular Hemodiafiltration', American Journal of Kidney Diseases, vol. 68, pp. 990 - 992, http://dx.doi.org/10.1053/j.ajkd.2016.08.017

Moon J; Kumar SS; Graham GG; Baysari MT; Williams KM; Chen W; Viardot A; Greenfield JR; Day RO, 2016, 'Trends in metformin utilisation and dose appropriateness in Australia', European Journal of Clinical Pharmacology, vol. 72, pp. 1489 - 1496, http://dx.doi.org/10.1007/s00228-016-2117-y

Rasheed H; McKinney C; Stamp LK; Dalbeth N; Topless RK; Day R; Kannangara D; Williams K; Smith M; Janssen M, 2016, 'The toll-like receptor 4 (TLR4) variant rs2149356 and risk of gout in European and polynesian sample sets', PLoS ONE, vol. 11, http://dx.doi.org/10.1371/journal.pone.0147939

Kannangara DRW; Phipps-Green AJ; Dalbeth N; Stamp LK; Williams KM; Graham GG; Day RO; Merriman TR, 2016, 'Hyperuricaemia: Contributions of urate transporter ABCG2 and the fractional renal clearance of urate', Annals of the Rheumatic Diseases, vol. 75, pp. 1363 - 1366, http://dx.doi.org/10.1136/annrheumdis-2015-208111

Kannangara DRW; Graham GG; Williams KM; Day RO, 2016, 'Effect of xanthine oxidase inhibitors on the renal clearance of uric acid and creatinine', Clinical Rheumatology, vol. 35, pp. 2375 - 2376, http://dx.doi.org/10.1007/s10067-015-3165-x

Hmar RC; Kannangara DRW; Ramasamy SN; Baysari MT; Williams KM; Day RO, 2015, 'Understanding and improving the use of allopurinol in a teaching hospital', Internal Medicine Journal, vol. 45, pp. 383 - 390, http://dx.doi.org/10.1111/imj.12701

Merriman TR; Stamp LK; Dalbeth N; Topless R; Day R; Kannangara D; Williams K; Janssen M; Jansen T; Joosten LA, 2015, 'Epistatic Interaction of Functional Inflammasome Genetic Variants in Determining the Risk of Gout', ARTHRITIS & RHEUMATOLOGY, vol. 67, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000370860204715&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Chung WH; Chang WC; Stocker SL; Juo CG; Graham GG; Lee MHH; Williams KM; Tian YC; Juan KC; Wu YJJ, 2015, 'Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: The impact of renal insufficiency, high plasma levels of oxypurinol and granulysin', Annals of the Rheumatic Diseases, vol. 74, pp. 2157 - 2164, http://dx.doi.org/10.1136/annrheumdis-2014-205577

McKinney C; Stamp LK; Dalbeth N; Topless RK; Day RO; Kannangara DRW; Williams KM; Janssen M; Jansen TL; Joosten LA, 2015, 'Multiplicative interaction of functional inflammasome genetic variants in determining the risk of gout', Arthritis Research and Therapy, http://dx.doi.org/10.1186/s13075-015-0802-3

Duong JK; Kumar SS; Furlong TJ; Kirkpatrick CM; Graham GG; Greenfield JR; Williams KM; Day RO, 2015, 'The pharmacokinetics of metformin and concentrations of haemoglobin A1C and lactate in Indigenous and non-Indigenous Australians with type 2 diabetes mellitus', British Journal of Clinical Pharmacology, vol. 79, pp. 617 - 623, http://dx.doi.org/10.1111/bcp.12525

Kannangara DRW; Graham GG; Williams KM; Day RO, 2014, 'Hypouricemic effects of prednisone and allopurinol: An uneven playing field?', Canadian Journal of Cardiology, vol. 30, pp. 376.e1, http://dx.doi.org/10.1016/j.cjca.2013.04.015

Ghosh D; Williams KM; Graham GG; Nair P; Buscher H; Day RO, 2014, 'Multiple episodes of aspirin overdose in an individual patient: A case report', Journal of Medical Case Reports, pp. 1 - 5, http://dx.doi.org/10.1186/1752-1947-8-374

Rasheed H; Topless R; Day R; Kannangara D; Williams K; Bradbury L; Brown M; Hill C; Lester S; Rischmueller M, 2014, 'Association of the Toll-like Receptor 4 (TLR4) Gene with Gout.', ARTHRITIS & RHEUMATOLOGY, vol. 66, pp. S1294 - S1295, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344384906196&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Kannangara DRW; Ramasamy SN; Ray JE; Jones G; Graham GG; Williams KM; Day RO, 2013, 'An audit of a therapeutic drug monitoring service for allopurinol therapy', Therapeutic Drug Monitoring, vol. 35, pp. 863 - 866, http://dx.doi.org/10.1097/FTD.0b013e318299920a

Ramasamy SN; Korb-Wells CS; Kannangara DRW; Smith MWH; Wang N; Roberts DM; Graham GG; Williams KM; Day RO, 2013, 'Allopurinol hypersensitivity: A systematic review of all published cases, 1950-2012', Drug Safety, vol. 36, pp. 953 - 980, http://dx.doi.org/10.1007/s40264-013-0084-0

Wong C; Kumar SS; Graham GG; Begg EJ; Chin PKL; Brett J; Ray JE; Marriott DJE; Williams KM; Day RO, 2013, 'Comparing dose prediction software used to manage gentamicin dosing', Internal Medicine Journal, vol. 43, pp. 519 - 525, http://dx.doi.org/10.1111/imj.12067

Day R; Lee H; Graham G; Williams K, 2013, 'Benzbromarone: Availability for general prescribing in New Zealand (a response to letters by Dr Lance Gravatt on benzbromarone)', New Zealand Medical Journal, vol. 126, pp. 124 - 126

Brett J; Chong O; Graham GG; Ray JE; Marriott D; Williams KM; Day RO, 2013, 'Antifungal use and therapeutic monitoring of plasma concentrations of itraconazole in heart and lung transplantation patients', Therapeutic Drug Monitoring, vol. 35, pp. 133 - 136, http://dx.doi.org/10.1097/FTD.0b013e318275fe69

Lee MHH; Stocker SL; Williams KM; Day RO, 2013, 'HLA-B*5801 should be used to screen for risk of Stevens-Johnson syndrome in family members of Han Chinese patients commencing allopurinol therapy', Journal of Rheumatology, vol. 40, pp. 96 - 97, http://dx.doi.org/10.3899/jrheum.120803

Stocker SL; Mclachlan AJ; Savic RM; Kirkpatrick CM; Graham GG; Williams KM; Day RO, 2012, 'The pharmacokinetics of oxypurinol in people with gout', British Journal of Clinical Pharmacology, vol. 74, pp. 477 - 489, http://dx.doi.org/10.1111/j.1365-2125.2012.04207.x

Kannangara DRW; Roberts DM; Furlong TJ; Graham GG; Williams KM; Day RO, 2012, 'Oxypurinol, allopurinol and allopurinol-1-riboside in plasma following an acute overdose of allopurinol in a patient with advanced chronic kidney disease', British Journal of Clinical Pharmacology, vol. 73, pp. 828 - 829, http://dx.doi.org/10.1111/j.1365-2125.2011.04147.x

Kannangara DRW; Ramasamy SN; Indraratna PL; Stocker SL; Graham GG; Jones G; Portek I; Williams KM; Day RO, 2012, 'Fractional clearance of urate: Validation of measurement in spot-urine samples in healthy subjects and gouty patients', Arthritis Research and Therapy, vol. 14, http://dx.doi.org/10.1186/ar4020

Duong JK; Roberts DM; Furlong TJ; Kumar SS; Greenfield JR; Kirkpatrick CM; Graham GG; Williams KM; Day RO, 2012, 'Metformin therapy in patients with chronic kidney disease', Diabetes, Obesity and Metabolism, vol. 14, pp. 963 - 965, http://dx.doi.org/10.1111/j.1463-1326.2012.01617.x

Lee MH; Stocker SL; Anderson J; Phillips EJ; Nolan D; Williams KM; Graham GG; Sullivan JR; Day RO, 2012, 'Initiating allopurinol therapy: Do we need to know the patient's human leucocyte antigen status?', Internal Medicine Journal, vol. 42, pp. 411 - 416, http://dx.doi.org/10.1111/j.1445-5994.2011.02567.x

Milder TY; Williams KM; Ritchie JE; Lipworth WL; Day RO, 2011, 'Use of NSAIDs for osteoarthritis amongst older-aged primary care patients: Engagement with information and perceptions of risk', Age and Ageing, vol. 40, pp. 254 - 259, http://dx.doi.org/10.1093/ageing/afq160

Milder TY; Lipworth WL; Williams KM; Ritchie JE; Day RO, 2011, '"It looks after me": How older patients make decisions about analgesics for osteoarthritis', Arthritis Care and Research, vol. 63, pp. 1280 - 1286, http://dx.doi.org/10.1002/acr.20514

Stocker SL; Graham GG; McLachlan AJ; Williams KM; Day RO, 2011, 'Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout', Journal of Rheumatology, vol. 38, pp. 904 - 910, http://dx.doi.org/10.3899/jrheum.101160

Ng DY; Stocker SL; Graham GG; Williams KM; Day RO, 2011, 'Lack of effect of hydrochlorothiazide and low-dose aspirin on the renal clearance of urate and oxypurinol after a single dose of allopurinol in normal volunteers', European Journal of Clinical Pharmacology, vol. 67, pp. 709 - 713, http://dx.doi.org/10.1007/s00228-010-0963-6

Graham GG; Punt J; Arora M; Day RO; Doogue MP; Duong JK; Furlong TJ; Greenfield JR; Greenup LC; Kirkpatrick CM, 2011, 'Clinical pharmacokinetics of metformin', Clinical Pharmacokinetics, vol. 50, pp. 81 - 98, http://dx.doi.org/10.2165/11534750-000000000-00000

Wang N; Lipworth WL; Ritchie JE; Williams KM; Day RO, 2011, 'Eliciting views of Australian pharmaceutical industry employees on collaboration and the concept of Quality Use of Medicines', Internal Medicine Journal, vol. 41, pp. 314 - 320, http://dx.doi.org/10.1111/j.1445-5994.2010.02239.x

Day RO; Liauw W; Tozer LMR; McElduff P; Beckett RJ; Williams KM, 2010, 'A double-blind, placebo-controlled study of the short term effects of a spring water supplemented with magnesium bicarbonate on acid/base balance, bone metabolism and cardiovascular risk factors in po', BMC Research Notes, vol. 3, http://dx.doi.org/10.1186/1756-0500-3-180

Palmer H; Graham G; Williams K; Day R, 2010, 'A Risk-Benefit Assessment of Paracetamol (Acetaminophen) Combined with Caffeine', Pain Medicine, vol. 11, pp. 951 - 965, http://dx.doi.org/10.1111/j.1526-4637.2010.00867.x

Stocker SL; Franklin ME; Anderson JM; Pillans PI; Williams KM; McLachlan AJ; Day RO; Taylor PJ, 2010, 'Measurement of urinary oxypurinol by high performance liquid chromatography-tandem mass spectrometry', Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol. 878, pp. 2363 - 2368, http://dx.doi.org/10.1016/j.jchromb.2010.07.017

Indraratna PL; Stocker SL; Williams KM; Graham GG; Jones G; Day RO, 2010, 'A proposal for identifying the low renal uric acid clearance phenotype', Arthritis Research and Therapy, vol. 12, http://dx.doi.org/10.1186/ar3191

Abdul MIM; Jiang X; Williams KM; Day RO; Roufogalis BD; Liauw WS; Xu H; Matthias A; Lehmann RP; McLachlan AJ, 2010, 'Pharmacokinetic and pharmacodynamic interactions of echinacea and policosanol with warfarin in healthy subjects', British Journal of Clinical Pharmacology, vol. 69, pp. 508 - 515, http://dx.doi.org/10.1111/j.1365-2125.2010.03620.x

Indraratna PL; Williams KM; Graham GG; Day RO, 2009, 'Hyperuricemia, cardiovascular disease, and the metabolic syndrome', Journal of Rheumatology, vol. 36, pp. 2842 - 2843, http://dx.doi.org/10.3899/jrheum.090500

Pett SL; McCarthy MC; Cooper DA; MacRae K; Tendolkar A; Norris R; Strizki JM; Williams KM; Emery S, 2009, 'A phase I study to explore the activity and safety of SCH532706, a small molecular chemokine receptor-5 antagonist in HIV type-1-infected patients', Antiviral Therapy, vol. 14, pp. 111 - 115

Burrell C; Booy R; Wood N; Egan AM; Taverner D; Williams K; Liauw W; Moskwa A; Pepin-Covatta S; Saville M, 2008, 'Immunogenicity of a reduced dose of A/H3N2 in the 2005 southern hemisphere formulation of inactivated split influenza vaccine', Influenza and other Respiratory Viruses, vol. 2, pp. 93 - 98, http://dx.doi.org/10.1111/j.1750-2659.2008.00039.x

McLachlan A; Day R; Williams K; Graham G; Stocker S, 2008, 'Maximising gout therapy', Australian Journal of Pharmacy, vol. 89, pp. 86 - 88

Lu CY; Williams K; Day R, 2008, 'Access to biologic medicines for the treatment of rheumatic diseases: Lessons from Australia', International Journal of Rheumatic Diseases, vol. 11, pp. 11 - 14, http://dx.doi.org/10.1111/j.1756-185X.2008.00322.x

Lu CY; Macneill P; Williams K; Day R, 2008, 'Access to high cost medicines in Australia: Ethical perspectives', Australia and New Zealand Health Policy, vol. 5, http://dx.doi.org/10.1186/1743-8462-5-4

Stocker SL; Williams KM; McLachlan AJ; Graham GG; Day RO, 2008, 'Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects', Clinical Pharmacokinetics, vol. 47, pp. 111 - 118, http://dx.doi.org/10.2165/00003088-200847020-00004

Lee MHH; Graham GG; Williams KM; Day RO, 2008, 'A benefit-risk assessment of benzbromarone in the treatment of gout: Was its withdrawal from the market in the best interest of patients?', Drug Safety, vol. 31, pp. 643 - 665, http://dx.doi.org/10.2165/00002018-200831080-00002

Xu H; Williams KM; Liauw WS; Murray M; Day RO; McLachlan AJ, 2008, 'Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide', British Journal of Pharmacology, vol. 153, pp. 1579 - 1586, http://dx.doi.org/10.1038/sj.bjp.0707685

Mohammed Abdul MI; Jiang X; Williams KM; Day RO; Roufogalis BD; Liauw WS; Xu H; McLachlan AJ, 2008, 'Pharmacodynamic interaction of warfarin with cranberry but not with garlic in healthy subjects', British Journal of Pharmacology, vol. 154, pp. 1691 - 1700, http://dx.doi.org/10.1038/bjp.2008.210

Day RO; Williams KM, 2007, 'Open-label extension studies: Do they provide meaningful information on the safety of new drugs?', Drug Safety, vol. 30, pp. 93 - 105, http://dx.doi.org/10.2165/00002018-200730020-00001

Lu CY; Williams KM; Day RO, 2007, 'Has the use of disease-modifying anti-rheumatic drugs changed as a consequence of controlled access to high-cost biological agents through the Pharmaceutical Benefits Scheme?', Internal Medicine Journal, vol. 37, pp. 601 - 606, http://dx.doi.org/10.1111/j.1445-5994.2007.01396.x

Lu CY; Williams KM; Day RO, 2007, 'The funding and use of high-cost medicines in Australia: The example of anti-rheumatic biological medicines', Australia and New Zealand Health Policy, vol. 4, http://dx.doi.org/10.1186/1743-8462-4-2

Day RO; Graham G; Williams K, 2007, 'Fenofibratewarfarin interaction [1]', Australian Prescriber, vol. 30, pp. 32

Lu CY; Ritchie J; Williams K; Day R, 2007, 'The views of stakeholders on controlled access schemes for high-cost antirheumatic biological medicines in Australia', Australia and New Zealand Health Policy, vol. 4, http://dx.doi.org/10.1186/1743-8462-4-26

Day RO; Graham GG; Hicks M; McLachlan AJ; Stocker SL; Williams KM, 2007, 'Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol', Clinical Pharmacokinetics, vol. 46, pp. 623 - 644, http://dx.doi.org/10.2165/00003088-200746080-00001

Winston A; Mallon PWG; Satchell C; MacRae K; Williams KM; Schutz M; Law M; Cooper DA; Emery S, 2007, 'The safety, efficacy and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulation', Clinical Infectious Diseases, vol. 44, pp. 1475 - 1483, http://dx.doi.org/10.1086/517507

Lu CY; Williams KM; Day RO, 2006, 'Utilisation of anti-rheumatic drugs in Australia: Impact of introducing high-cost biologics under the pharmaceutical benefits scheme', PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, vol. 15, pp. S213 - S213, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000240281200457&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lu CY; Williams KM; Day RO, 2006, 'Access to high-cost medicines for the treatment of rheumatoid arthritis under Australia's pharmaceutical benefits scheme', PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, vol. 15, pp. S213 - S213, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000240281200458&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Loboz KK; Gross AS; Williams KM; Liauw WS; Day RO; Blievernicht JK; Zanger UM; McLachlan AJ, 2006, 'Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: Effect of induction by rifampin and ethnicity', Clinical Pharmacology and Therapeutics, vol. 80, pp. 75 - 84, http://dx.doi.org/10.1016/j.clpt.2006.03.010

Lu CY; Williams KM; Day RO, 2006, 'Access to tumour necrosis factor inhibitors for rheumatoid arthritis treatment under the Australian Pharmaceutical Benefits Scheme: Are we on target?', Internal Medicine Journal, vol. 36, pp. 19 - 27, http://dx.doi.org/10.1111/j.1445-5994.2005.00992.x

Lu CY; Williams KM; Day RO, 2006, 'Accessing health outcome data on high-cost medicines in Australia', Medical Journal of Australia, vol. 184, pp. 411 - 413

Lu CY; Ritchie J; Williams KM; Day RO, 2005, 'Recent developments in targeting access to high cost medicines in Australia', Australia and New Zealand Health Policy, vol. 2, http://dx.doi.org/10.1186/1743-8462-2-28

Mallon PWG; Unemori P; Sedwell R; Morey A; Rafferty M; Williams K; Chisholm D; Samaras K; Emery S; Kelleher A, 2005, 'In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA', Journal of Infectious Diseases, vol. 191, pp. 1686 - 1696, http://dx.doi.org/10.1086/429697

Jiang X; Williams KM; Liauw WS; Ammit AJ; Roufogalis BD; Duke CC; Day RO; McLachlan AJ, 2005, 'Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects', British Journal of Clinical Pharmacology, vol. 59, pp. 425 - 432, http://dx.doi.org/10.1111/j.1365-2125.2005.02322.x

Lee EJD; Williams K; Day R; Graham G; Champion D; Geisslinger G, 2004, 'Stereoselective disposition of ibuprofen enantiomers in man', British Journal of Clinical Pharmacology, vol. 58

Mallon PWG; Sedwell R; Unemori P; Merlin K; McGinley C; Ammaranond P; Peperias M; Rafferty M; Williams K; Samaras K, 2004, 'Nucleoside reverse transcriptase inhibitors (NRTI) decrease adipocyte and monocyte mitochondrial (mt) messenger RNA transcription in the absence of changes in mtDNA or cell morphology', ANTIVIRAL THERAPY, vol. 9, pp. L56 - L57, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000231616000126&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Mallon PWG; Sedwell R; Unemori P; Rafferty M; Williams K; Chisholm D; Samaras K; Emery S; Kelleher A; Cooper DA, 2004, 'Changes in nuclear gene expression resulting from NRTI-induced inhibition of mitochondrial transcription reveal links between mitochondrial dysfunction and lipid metabolism', ANTIVIRAL THERAPY, vol. 9, pp. L56 - L56, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000231616000125&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Mallon PWG; Unemori P; Sedwell R; Morey A; Rafferty M; Williams K; Chisholm D; Samaras K; Emery S; Kelleher A, 2004, 'In vivo nucleoside reverse transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes independent to HIV infection', ANTIVIRAL THERAPY, vol. 9, pp. L11 - L11, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000231616000044&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Jiang X; Williams KM; Liauw W; Ammit AJ; Roufogalis BD; Duke CC; Day RO; McLachlan AJ, 2004, 'Pharmacokinetic-pharmacodynamic modelling to investigate herb-drug interactions with warfarin', CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, vol. 31, pp. A227 - A227, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000225490400052&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lu CY; Williams K; Day R; March L; Sansom L; Bertouch J, 2004, 'Access to high cost drugs in Australia', British Medical Journal, vol. 329, pp. 415 - 416

Lee EJD; Williams K; Day R; Graham G; Champion D; Geisslinger G, 2004, 'Stereoselective disposition of ibuprofen enantiomers in man', British Journal of Clinical Pharmacology, vol. 58

Lomas M; Liauw W; Packham D; Williams K; Kelleher A; Zaunders J; Ward R, 2004, 'Phase I clinical trial of a human idiotypic p53 vaccine in patients with advanced malignancy', Annals of Oncology, vol. 15, pp. 324 - 329, http://dx.doi.org/10.1093/annonc/mdh053

Jiang X; Williams KM; Liauw WS; Ammit AJ; Roufogalis BD; Duke CC; Day RO; McLachlan AJ, 2004, 'Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects', British Journal of Clinical Pharmacology, vol. 57, pp. 592 - 599, http://dx.doi.org/10.1111/j.1365-2125.2003.02051.x

Jiang X; Williams KM; Liauw WS; Ammit AJ; Roufogalis BD; Duke CC; Day RO; McLachlan AJ, 2004, 'Erratum: Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects (British Journal of Clinical Pharmacology (2004) 57 (592-599))', British Journal of Clinical Pharmacology, vol. 58, pp. 102, http://dx.doi.org/10.1111/j.1365-2125.2004.02155.x

Lu CY; Williams KM; March L; Bertouch JV; Day RO; Sansom LN, 2004, 'Subsidised access to TNFα inhibitors: Is the rationale for exclusion of rheumatoid-factor-negative patients defensible? (multiple letters) [1]', Medical Journal of Australia, vol. 181, pp. 457 - 458

Pett SL; Williams LA; Day RO; Lloyd AR; Carr AD; Clezy KR; Emery S; Kaplan E; McPhee DA; McLachlan AJ, 2004, 'A phase I study of the pharmacokinetics and safety of passive immunotherapy with caprine anti-HIV antibodies, ^PEHRG214, in HIV-1-infected individuals', HIV Clinical Trials, vol. 5, pp. 91 - 98, http://dx.doi.org/10.1310/1FLN-8KFC-5HEQ-K19J

Liauw WS; Williams KM; Day RO, 2004, 'Protocol Appraisal: A Study Site's Viewpoint', Applied Clinical Trials, vol. 13, pp. 34 - 42

Williams KM, 2004, 'Stereoselective disposition of ibuprofen enantiomers in man - Author's commentary', British Journal of Clinical Pharmacology, vol. 58, pp. S765 - S766

Sasongko L; Williams KM; Day RO; McLachlan AJ, 2003, 'Human subcutaneous tissue distribution of fluconazole: Comparison of microdialysis and suction blister techniques', British Journal of Clinical Pharmacology, vol. 56, pp. 551 - 561, http://dx.doi.org/10.1046/j.1365-2125.2003.01930.x

Wren BG; Day RO; McLachlan AJ; Williams KM, 2003, 'Pharmacokinetics of estradiol, progesterone, testosterone and dehydroepiandrosterone after transbuccal administration to postmenopausal women', Climacteric, vol. 6, pp. 104 - 111, http://dx.doi.org/10.1080/cmt.6.2.104.111

Sasongko L; Ramzan I; Williams KM; McLachlan AJ, 2002, 'Muscle distribution of the neuromuscular blocker gallamine using microdialysis', Journal of Pharmaceutical Sciences, vol. 91, pp. 769 - 775, http://dx.doi.org/10.1002/jps.10082

Sasongko L; Ramzan I; Williams KM; McLachlan AJ, 2001, 'Application of a high-performance liquid chromatographic assay for the neuromuscular blocker gallamine to analysis of rat plasma, muscle and microdialysate samples', Journal of Chromatography B: Biomedical Sciences and Applications, vol. 754, pp. 467 - 475, http://dx.doi.org/10.1016/S0378-4347(01)00032-9

Campbell TJ; Williams KM, 2001, 'Therapeutic drug monitoring: Antiarrhythmic drugs', British Journal of Clinical Pharmacology, vol. 52

Williams KM; Cooper S; Parisis K; Handel M; Day RO, 2001, 'The skin suction blister: A human model of inflammation', Clinical Pharmacology and Therapeutics, vol. 69

Sasongko L; Williams KM; Ramzan I; McLachlan AJ, 2000, 'Assessment of in vitro and in vivo recovery of gallamine using microdialysis', Journal of Pharmacological and Toxicological Methods, vol. 44, pp. 519 - 525, http://dx.doi.org/10.1016/S1056-8719(00)00117-9

Davies NM; McLachlan AJ; Day RO; Williams KM, 2000, 'Clinical pharmacokinetics and pharmacodynamics of celecoxib. A selective cyclo-oxygenase-2 inhibitor', Clinical Pharmacokinetics, vol. 38, pp. 225 - 242, http://dx.doi.org/10.2165/00003088-200038030-00003

Williams KM; Day RO; Roberts LK; Harbin JA, 1999, 'A comparison of the efficacy of α-ketobutyric acid (KBA), nordihidro-guaiaretic acid (NDGA), salicylic acid (SA), and placebo (P) in the accelerated removal of corns', Clinical Pharmacology and Therapeutics, vol. 65, pp. 122, http://dx.doi.org/10.1016/S0009-9236(99)80022-8

Browne GS; Nelson C; Nguyen T; Ellis BA; Day RO; Williams KM, 1999, 'Stereoselective and substrate-dependent inhibition of hepatic mitochondrial β-oxidation and oxidative phosphorylation by the non-steroidal anti inflammatory drugs ibuprofen, flurbiprofen, and ketorola', Biochemical Pharmacology, vol. 57, pp. 837 - 844, http://dx.doi.org/10.1016/S0006-2952(98)00342-6

Day RO; McLachlan AJ; Graham GG; Williams KM, 1999, 'Pharmacokinetics of nonsteroidal anti-inflammatory drugs in synovial fluid', Clinical Pharmacokinetics, vol. 36, pp. 191 - 210, http://dx.doi.org/10.2165/00003088-199936030-00002

Scheuerer S; Hall SD; Williams KM; Geisslinger G, 1998, 'Effect of clofibrate on the chiral inversion of ibuprofen in healthy volunteers.', Clin Pharmacol Ther, vol. 64, pp. 168 - 176, http://dx.doi.org/10.1016/S0009-9236(98)90150-3

Campbell TJ; Williams KM, 1998, 'Therapeutic drug monitoring: Antiarrhythmic drugs', British Journal of Clinical Pharmacology, vol. 46, pp. 307 - 319, http://dx.doi.org/10.1046/j.1365-2125.1998.t01-1-00768.x

Scheuerer S; Williams KM; Brugger R; Mclachlan AJ; Brune K; Day RO; Geisslinger G, 1998, 'Effect of clofibrate on the chiral disposition of ibuprofen in rats', Journal of Pharmacology and Experimental Therapeutics, vol. 284, pp. 1132 - 1138

Day RO; Chalmers DRC; Williams KM; Campbell TJ, 1998, 'The death of a healthy volunteer in a human research project: Implications for Australian clinical research', Medical Journal of Australia, vol. 168, pp. 449 - 451

Donnelly R; Williams KM; Baker AB; Badcock CA; Day RO; Seale JP, 1997, 'Effects of budesonide and fluticasone on 24-hour plasma cortisol: A dose-response study', American Journal of Respiratory and Critical Care Medicine, vol. 156, pp. 1746 - 1751, http://dx.doi.org/10.1164/ajrccm.156.6.9703003

Williams KM; Turner J; Geisslinger G; Day RO, 1997, 'The suction blister as an in vivo model of inflammation: Interblister variability and preliminary studies of the disposition of methotrexate', Clinical Pharmacology and Therapeutics, vol. 61, pp. 160

Williams KM; Turner J; Geisslinger G; Day RO, 1997, 'The suction blister as an in vivo model of inflammation: Interblister variability and preliminary studies of the disposition of methotrexate', CLINICAL PHARMACOLOGY & THERAPEUTICS, vol. 61, pp. PI93 - PI93, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1997WJ68400093&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Oelkers R; Neupert W; Williams KM; Brune K; Geisslinger G, 1997, 'Disposition and effects of flurbiprofen enantiomers in human serum and blister fluid', British Journal of Clinical Pharmacology, vol. 43, pp. 145 - 153

Wang X; Liu Y; Nair UB; Armstrong DW; Ellis B; Williams KM, 1997, 'Enantiomeric composition of monoterpenes in conifer resins', Tetrahedron - Asymmetry, pp. 3977 - 3984

Simkin PA; Bassett JE; Lapicque F; Bertin P; Netter P; Day RO; Williams KM; Geisslinger G, 1996, 'Naproxen concentration in plasma and synovial fluid and effects on prostanoid concentrations [1]', Journal of Rheumatology, vol. 23, pp. 1826 - 1828

Day RO; Williams KM; Geisslinger G, 1996, 'Naproxen concentrations in plasma and synovial fluid and effects on prostanoid concentrations - Reply', JOURNAL OF RHEUMATOLOGY, vol. 23, pp. 1827 - 1828, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1996VL78300035&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Zachara NE; Packer NH; Temple MD; Slade MB; Jardine DR; Karuso P; Moss CJ; Mabbutt BC; Curmi PMG; Williams KL, 1996, 'Recombinant prespore-specific antigen from Dictyostelium discoideum is a β-sheet glycoprotein with a spacer peptide modified by O-linked N-acetylglucosamine', European Journal of Biochemistry, vol. 238, pp. 511 - 518, http://dx.doi.org/10.1111/j.1432-1033.1996.0511z.x

Soong R; Knowles S; Williams KM; Hammond IG; Wysocki SJ; Iacopetta BJ, 1996, 'Overexpression of p53 protein is an independent prognostic indicator in human endometrial carcinoma', British Journal of Cancer, pp. 562 - 567

McLachlan AJ; Williams KM, 1995, 'Estimation of the rate and extent of chiral inversion using linear systems analysis', Chirality, vol. 7, pp. 632 - 635, http://dx.doi.org/10.1002/chir.530070814

Day RO; Geisslinger G; Paull P; Williams KM, 1995, 'The effect of tenoxicam on tolbutamide pharmacokinetics and glucose concentrations in healthy volunteers', International Journal of Clinical Pharmacology and Therapeutics, vol. 33, pp. 308 - 310

Day RO; Francis H; Vial J; Geisslinger G; Williams KM, 1995, 'Naproxen concentrations in plasma and synovial fluid and effects on prostanoid concentrations', Journal of Rheumatology, vol. 22, pp. 2295 - 2303

Wasinger VC; Cordwell SJ; Poljak A; Yan JX; Gooley AA; Wilkins MR; Duncan MW; Harris R; Williams KL; Humphery‐Smith I, 1995, 'Progress with gene‐product mapping of the Mollicutes: Mycoplasma genitalium', ELECTROPHORESIS, vol. 16, pp. 1090 - 1094, http://dx.doi.org/10.1002/elps.11501601185

Cordwell SJ; Wilkins MR; Poljak A; Gooley AA; Duncan M; Williams KL; Humphery‐Smith I, 1995, 'Cross‐species identification of proteins separated by two‐dimensional gel electrophoresis using matrix‐assisted laser desorption ionisation/time‐of‐flight mass spectrometry and amino acid composition', ELECTROPHORESIS, vol. 16, pp. 438 - 443, http://dx.doi.org/10.1002/elps.1150160171

Walsh BJ; Gooley AA; Williams KL; Breit SN, 1995, 'Identification of macrophage activation associated proteins by two-dimensional gel electrophoresis and microsequencing', Journal of Leukocyte Biology, vol. 57, pp. 507 - 512, http://dx.doi.org/10.1002/jlb.57.3.507

Day RO; Francis H; Vial JH; Geisslinger G; Williams KM, 1995, 'Pharmacokinetics and pharmacodynamics of naproxen in synovial fluid and plasma', Journal of Rheumatology, pp. 2295 - 2303

Seideman P; Lohrer F; Graham G; Duncan M; Williams K; Day R, 1994, 'The stereoselective disposition of the enantiomers of ibuprofen in blood, blister and synovial fluid.', British Journal of Clinical Pharmacology, vol. 38, pp. 221 - 227, http://dx.doi.org/10.1111/j.1365-2125.1994.tb04345.x

Day R; Geisslinger G; Paull P; Williams K, 1994, 'Neither cimetidine nor probenecid affect the pharmacokinetics of tenoxicam in normal volunteers.', British Journal of Clinical Pharmacology, vol. 37, pp. 79 - 81, http://dx.doi.org/10.1111/j.1365-2125.1994.tb04244.x

Brooks PM; Day RO; Graham GG; Williams KM, 1993, 'Preface', Agents and Actions, vol. 44

DAY RO; NGUYEN T; WILLIAMS KM, 1993, 'TENOXICAM DOSE CONCENTRATION RESPONSE RELATIONSHIP IN RHEUMATOID-ARTHRITIS (RA)', CLINICAL PHARMACOLOGY & THERAPEUTICS, vol. 53, pp. 152 - 152, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1993KP26900067&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Williams KM, 1993, 'Chiral NSAIDs: So what?', Agents and Actions, vol. 44, pp. 15 - 22

Day RO; Brooks PM; Williams KM; Graham GG, 1993, 'Third World conference on variability in response to anti-rheumatic drugs, Singapore, July 22-24, 1992.', Agents and actions, vol. 38

Williams KM; Day RO; Breit SN, 1993, 'Biochemical actions and clinical pharmacology of anti-inflammatory drugs', Advances in Drug Research, vol. 24, pp. 121 - 198

Day RO; Brooks PM; Williams KM; Graham GG, 1993, 'Meeting report: Third world conference on variability in response to anti-rheumatic drugs, Singapore, July 22-24, 1992', Agents and Actions, vol. 38

Zhao B; Geisslinger G; Hall I; Day RO; Williams KM, 1992, 'The effect of the enantiomers of ibuprofen and flurbiprofen on the β‐oxidation of palmitate in the rat', Chirality, vol. 4, pp. 137 - 141, http://dx.doi.org/10.1002/chir.530040302

Williams KM, 1991, 'Molecular Asymmetry and Its Pharmacological Consequences', Advances in Pharmacology, vol. 22, pp. 57 - 135, http://dx.doi.org/10.1016/S1054-3589(08)60033-2

Day RO; Williams KM; Graham S; Handel M, 1991, 'The pharmacokinetics of total and unbound concentrations of tenoxicam in synovial fluid and plasma', Arthritis & Rheumatism, vol. 34, pp. 751 - 760, http://dx.doi.org/10.1002/art.1780340617

Knihinicki RD; Day RO; Williams KM, 1991, 'Chiral inversion of 2-arylpropionic acid non-steroidal anti-inflammatory drugs-II Racemization and hydrolysis of (R)- and (S)-ibuprofen-CoA thioesters', Biochemical Pharmacology, vol. 42, pp. 1905 - 1911, http://dx.doi.org/10.1016/0006-2952(91)90588-V

Williams KM; Knihinicki RD; Day RO, 1991, 'Pharmacokinetics of the enantiomers of ibuprofen in the rabbit', Agents and Actions, vol. 34, pp. 381 - 386, http://dx.doi.org/10.1007/BF01988732

Lee EJD; Willia KM, 1990, 'Chirality Clinical Pharmacokinetic and Pharmacodynamic Considerations', Clinical Pharmacokinetics, vol. 18, pp. 339 - 345, http://dx.doi.org/10.2165/00003088-199018050-00001

Nuernberg B; Knihinicki R; Williams K; Freeman GE; Dalton C; Brooks PM; Day RO, 1990, 'Anti-inflammatory effects and disposition of S- and R-flurbiprofen in the rat', European Journal of Pharmacology, vol. 183, pp. 1591 - 1592, http://dx.doi.org/10.1016/0014-2999(90)94757-O

Williams KM, 1990, 'Enantiomers in arthritic disorders', Pharmacology and Therapeutics, vol. 46, pp. 273 - 295, http://dx.doi.org/10.1016/0163-7258(90)90095-J

Knihinicki RD; Day RO; Graham GG; Williams KM, 1990, 'Stereoselective disposition of ibuprofen and flurbiprofen in rats', Chirality, vol. 2, pp. 134 - 140, http://dx.doi.org/10.1002/chir.530020303

Williams KM, 1989, 'CHIRALITY: PHARMACOKINETICS AND PHARMACODYNAMICS IN 3 DIMENSIONS', Clinical and Experimental Pharmacology and Physiology, vol. 16, pp. 465 - 470, http://dx.doi.org/10.1111/j.1440-1681.1989.tb01589.x

Knihinicki RD; Williams KM; Day RO, 1989, 'Chiral inversion of 2-arylpropionic acid non-steroidal anti-inflammatory drugs-1. In vitro studies of ibuprofen and flurbiprofen', Biochemical Pharmacology, vol. 38, pp. 4389 - 4395, http://dx.doi.org/10.1016/0006-2952(89)90647-3

Williams KM; Day RO, 1988, 'The contribution of enantiomers to variability in response to anti-inflammatory drugs.', Agents and actions. Supplements, vol. 24, pp. 76 - 84

Day R; Paull P; Lam S; Swanson B; Williams K; Wade D, 1988, 'The effect of concurrent aspirin upon plasma concentrations of tenoxicam.', British Journal of Clinical Pharmacology, vol. 26, pp. 455 - 462, http://dx.doi.org/10.1111/j.1365-2125.1988.tb03405.x

Day RO; Williams KM; Graham GG; Lee EJ; Knihinicki RD; Champion GD, 1988, 'Stereoselective disposition of ibuprofen enantiomers in synovial fluid', Clinical Pharmacology and Therapeutics, vol. 43, pp. 480 - 487, http://dx.doi.org/10.1038/clpt.1988.62

Day RO; Graham GG; Willia KM; Brooks PM, 1988, 'Variability in Response to NSAIDs: Fact or Fiction?', Drugs, vol. 36, pp. 643 - 651, http://dx.doi.org/10.2165/00003495-198836060-00001

Day RO; Graham GG; Williams KM, 1988, 'Pharmacokinetics of non-steroidal anti-inflammatory drugs', Bailliere's Clinical Rheumatology, vol. 2, pp. 363 - 393, http://dx.doi.org/10.1016/S0950-3579(88)80019-0

Day RO; Graham GG; Williams KM; David Champion G; de Jager J, 1987, 'Clinical pharmacology of non-steroidal anti-inflammatory drugs', Pharmacology and Therapeutics, vol. 33, pp. 383 - 433, http://dx.doi.org/10.1016/0163-7258(87)90072-6

Williams K; Day R; Knihinicki R; Duffield A, 1986, 'The stereoselective uptake of ibuprofen enantiomers into adipose tissue', Biochemical Pharmacology, vol. 35, pp. 3403 - 3405, http://dx.doi.org/10.1016/0006-2952(86)90443-0

WILLIAMS KM; DAY RO; KNIHINICKI RD; DUFFIELD AM, 1986, 'STEREOSELECTIVE INCORPORATION OF IBUPROFEN ENANTIOMERS INTO ADIPOSE-TISSUE IN RATS AND MAN', ACTA PHARMACOLOGICA ET TOXICOLOGICA, vol. 59, pp. 192 - 192, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1986D896000552&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Williams KM; Day RO, 1985, 'Stereoselective disposition--basis for variability in response to NSAID's.', Agents and actions. Supplements, vol. 17, pp. 119 - 126

Lee E; Williams K; Day R; Graham G; Champion D, 1985, 'Stereoselective disposition of ibuprofen enantiomers in man.', British Journal of Clinical Pharmacology, vol. 19, pp. 669 - 674, http://dx.doi.org/10.1111/j.1365-2125.1985.tb02694.x

DAY RO; WILLIAMS KM; LEE EJ; KNIHINICKI R, 1985, 'DISPOSITION OF ENANTIOMERS OF IBUPROFEN IN PLASMA AND SYNOVIAL-FLUID IN ARTHRITIC DISEASE', CLINICAL AND INVESTIGATIVE MEDICINE-MEDECINE CLINIQUE ET EXPERIMENTALE, vol. 8, pp. A58 - A58, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1985AQS8500134&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Williams KM, 1984, 'Kinetics of misonidazole enantiomers', Clinical Pharmacology and Therapeutics, vol. 36, pp. 817 - 823, http://dx.doi.org/10.1038/clpt.1984.262

Lee EJD; Williams KM; Graham GG; Day RO; Champion GD, 1984, 'Liquid chromatographic determination and plasma concentration profile of optical isomers of ibuprofen in humans', Journal of Pharmaceutical Sciences, vol. 73, pp. 1542 - 1544, http://dx.doi.org/10.1002/jps.2600731112

Begg EJ; Williams KM; Wade DN; O'Shea KF, 1983, 'No significant effect of cimetidine on the pharmacokinetics of misonidazole in man.', Br J Clin Pharmacol, vol. 15, pp. 575 - 576, http://dx.doi.org/10.1111/j.1365-2125.1983.tb02096.x

WILLIAMS KM; BEGG EJ; WADE DN; OSHEA K, 1983, 'THE EFFECT OF CIMETIDINE AND METOCLOPRAMIDE ON THE ELIMINATION OF MISONIDAZOLE (RO-07-0582) IN MAN', CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, vol. 10, pp. 718 - 719, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1983RW31100131&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Williams K; Begg E; Wade D; O'Shea K, 1983, 'Effects of phenytoin, phenobarbital, and ascorbic acid on misonidazole elimination', Clinical Pharmacology and Therapeutics, vol. 33, pp. 314 - 321, http://dx.doi.org/10.1038/clpt.1983.39

Begg E; Williams K; Wade D; O'Shea K, 1983, 'No significant effect of cimetidine on the pharmacokinetics of misonidazole in man.', British Journal of Clinical Pharmacology, vol. 15, pp. 575 - 576, http://dx.doi.org/10.1111/j.1365-2125.1983.tb02096.x

Williams K; Begg E; Wade D; O'Shea K, 1983, 'No significant effect of metoclopramide on misonidazole elimination in man.', British Journal of Clinical Pharmacology, vol. 15, pp. 390 - 392, http://dx.doi.org/10.1111/j.1365-2125.1983.tb01519.x

Tung C; Graham GG; Wade DN; Williams KM, 1982, 'The pharmacokinetics of chlorbutol in man', Biopharmaceutics & Drug Disposition, vol. 3, pp. 371 - 378, http://dx.doi.org/10.1002/bdd.2510030410

CHINWAY PM; WILLIAMS KM; WADE DN, 1982, 'A STUDY OF THE DISTRIBUTION AND ELIMINATION OF HIGH-DOSES OF DPH IN RABBITS', CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, vol. 9, pp. 459 - 460, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1982PJ26400121&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Williams KM; Begg EJ; Wade DN; O'Shea K, 1982, 'The effect of phenytoin, phenobarbitone and ascorbic acid on the elimination of misonidazole (Ro 07-0582) in man', Clinical and Experimental Pharmacology and Physiology, vol. 9, pp. 423

Williams KM; Duffield AM; Christopher RK; Finlayson PJ, 1981, 'Identification of minor metabolites of 5‐fluorocytosine in man by chemical ionization gas chromatography mass spectrometry', Biological Mass Spectrometry, vol. 8, pp. 179 - 182, http://dx.doi.org/10.1002/bms.1200080410

WILLIAMS KM; DUFFIELD AM; CHRISTOPHER RK; FINLAYSON PJ, 1980, 'MINOR METABOLITES OF 5-FLUOROCYTOSINE IN MAN', CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, vol. 7, pp. 681 - 681, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1980KV12600077&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

TUNG C; GRAHAM GG; WADE DN; WILLIAMS KM, 1980, 'THE PHARMACOKINETICS OF CHLORBUTOL', CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, vol. 7, pp. 672 - 672, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1980KV12600062&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Borody T; Chinwah PM; Graham GG; Wade DN; Williams KM, 1979, 'Chlorbutol toxicity and dependence.', Med J Aust, vol. 1, pp. 288, https://www.ncbi.nlm.nih.gov/pubmed/449799

Ziegler JB; Graham GG; Day RO; Williams KM; Milligan MK, 1998, 'THERAPEUTIC CONSIDERATIONS FROM PHARMACOKINETICS AND METABOLISM: IBUPROFEN AND PARACETAMOL.', in Safety and Efficacy of non-prescription (OTC) analgesics and NSAIDs, Kluwer Academic Publishers, San Francisco, California USA, presented at Safety and Efficacy of non-prescription analgesics and NSAIDS, San Francisco, California USA, 17 - 01 March 1997